Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Cengiz Beyan
Esin Beyan
机构：
[1] Ufuk University Faculty of Medicine,Department of Internal Medicine
[2] University of Health Sciences,undefined
[3] Kecioren Training and Research Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Drug therapy; Mean platelet volume; Predictive value of tests; Prognosis; Prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2175 / 2176
页数：1
相关论文
共 50 条
  • [21] Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
    Armstrong, Andrew J.
    Eisenberger, Mario A.
    Halabi, Susan
    Oudard, Stephane
    Nanus, David M.
    Petrylak, Daniel P.
    Sartor, A. Oliver
    Scher, Howard I.
    EUROPEAN UROLOGY, 2012, 61 (03) : 549 - 559
  • [22] Simple Prognostic Score for Metastatic Castration-Resistant Prostate Cancer With Incorporation of Neutrophil-to-Lymphocyte Ratio
    Templeton, Arnoud J.
    Pezaro, Carmel
    Omlin, Aurelius
    McNamara, Mairead G.
    Leibowitz-Amit, Raya
    Vera-Badillo, Francisco E.
    Attard, Gerhardt
    de Bono, Johann S.
    Tannock, Ian F.
    Amir, Eitan
    CANCER, 2014, 120 (21) : 3346 - 3352
  • [23] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12) : 1231 - 1240
  • [24] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [25] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [26] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
    Tseng, Chi-Shin
    Yang, Jui-Han
    Huang, Shi-Wei
    Wang, Yu-Jen
    Chen, Chung-Hsin
    Pu, Yeong-Shiau
    Cheng, Jason Chia-Hsien
    Huang, Chao-Yuan
    BMC CANCER, 2023, 23 (01)
  • [27] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
    Chi-Shin Tseng
    Jui-Han Yang
    Shi-Wei Huang
    Yu-Jen Wang
    Chung-Hsin Chen
    Yeong-Shiau Pu
    Jason Chia-Hsien Cheng
    Chao-Yuan Huang
    BMC Cancer, 23
  • [28] Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide
    Caffo, Orazio
    Basso, Umberto
    Cattrini, Carlo
    Ermacora, Paola
    Maruzzo, Marco
    Alberti, Martina
    Anesi, Cecilia
    Bimbatti, Davide
    Cani, Massimiliano
    Crespi, Veronica
    Farinea, Giovanni
    Kadrija, Dzenete
    Kinspergher, Stefania
    Lai, Eleonora
    Lay, Ludovica
    Maines, Francesca
    Mennitto, Alessia
    Pierantoni, Francesco
    Samuelly, Alessandro
    Urban, Susanna
    Buttigliero, Consuelo
    Veccia, Antonello
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [29] Current Treatment Strategies for Castration-Resistant Prostate Cancer
    Kim, Se Joong
    Kim, Sun Il
    KOREAN JOURNAL OF UROLOGY, 2011, 52 (03) : 157 - 165
  • [30] Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer
    Caram, Megan E. V.
    Kumbier, Kyle
    Tsao, Phoebe A.
    Burns, Jennifer
    Sparks, Jordan B.
    Stensland, Kristian D.
    Reichert, Zachery R.
    Alumkal, Joshi J.
    Hollenbeck, Brent K.
    Shahinian, Vahakn
    Tsodikov, Alexander
    Skolarus, Ted A.
    CANCER MEDICINE, 2024, 13 (12):
12345